Aclaris Therapeutics Inc Dividends
The next dividend date for Aclaris Therapeutics Inc has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for Aclaris Therapeutics Inc (ACRS)
More About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Owning Aclaris Therapeutics Inc Stock on the Dividend Date
If you own Aclaris Therapeutics Inc stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of Aclaris Therapeutics Inc stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Aclaris Therapeutics Inc stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying Aclaris Therapeutics Inc stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Aclaris Therapeutics Inc dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More Aclaris Therapeutics Inc Dividends
You can contact us any time if you would like to ask questions about Aclaris Therapeutics Inc dividends or anything else related to the stock market.